3qiz
From Proteopedia
(Difference between revisions)
(3 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
+ | |||
==Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-2== | ==Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-2== | ||
- | <StructureSection load='3qiz' size='340' side='right' caption='[[3qiz]], [[Resolution|resolution]] 2.00Å' scene=''> | + | <StructureSection load='3qiz' size='340' side='right'caption='[[3qiz]], [[Resolution|resolution]] 2.00Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3qiz]] is a 1 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[3qiz]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Clostridium_botulinum_A_str._Hall Clostridium botulinum A str. Hall]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QIZ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QIZ FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=QI2:(2S,4R)-2-(2-{[3-(4-FLUORO-3-METHYLPHENYL)PROPYL](METHYL)AMINO}ETHYL)-4-(4-FLUOROPHENYL)-N-HYDROXY-4-METHOXYBUTANAMIDE'>QI2</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=QI2:(2S,4R)-2-(2-{[3-(4-FLUORO-3-METHYLPHENYL)PROPYL](METHYL)AMINO}ETHYL)-4-(4-FLUOROPHENYL)-N-HYDROXY-4-METHOXYBUTANAMIDE'>QI2</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |
- | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qiz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qiz OCA], [https://pdbe.org/3qiz PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qiz RCSB], [https://www.ebi.ac.uk/pdbsum/3qiz PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qiz ProSAT]</span></td></tr> | |
- | + | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | |
</table> | </table> | ||
- | <div style="background-color:#fffaf0;"> | ||
- | == Publication Abstract from PubMed == | ||
- | Neurotoxins synthesized by Clostridium botulinum bacteria (BoNT), the etiological agent of human botulism, are extremely toxic proteins making them high-risk agents for bioterrorism. Small molecule inhibitor development has been focused on the light chain zinc-dependent metalloprotease domain of the neurotoxin, an effort that has been hampered by its relatively flexible active site. Developed in concert with structure-activity relationship studies, the X-ray crystal structures of the complex of BoNT serotype A light chain (BoNT/A LC) with three different micromolar potency hydroxamate-based inhibitors are reported here for the first time. Comparison with an unliganded BoNT/A LC structure reveals significant changes in the active site as a result of binding by the unique inhibitor scaffolds. The 60/70 loop at the opening of the active site pocket undergoes the largest conformational change, presumably through an induced-fit mechanism, resulting in the most compact catalytic pocket observed in all known BoNT/A LC structures. | ||
- | |||
- | Structural Characterization of Three Novel Hydroxamate-based Zinc Chelating Inhibitors of the C. botulinum Serotype A Neurotoxin Light Chain Metalloprotease Reveals a Compact Binding Site Resulting from 60/70 Loop Flexibility.,Thompson AA, Jiao GS, Kim S, Thai A, Cregar-Hernandez L, Margosiak SA, Johnson AT, Han GW, O'Malley S, Stevens RC Biochemistry. 2011 Mar 24. PMID:21434688<ref>PMID:21434688</ref> | ||
- | + | ==See Also== | |
- | + | *[[Botulinum neurotoxin 3D structures|Botulinum neurotoxin 3D structures]] | |
- | == | + | |
- | + | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Clostridium botulinum A str. Hall]] |
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: Han | + | [[Category: Han GW]] |
- | [[Category: Stevens | + | [[Category: Stevens RC]] |
- | [[Category: Thompson | + | [[Category: Thompson AA]] |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Crystal Structure of BoNT/A LC complexed with Hydroxamate-based Inhibitor PT-2
|